Legislation to stimulate the development of drugs for rare diseases first came into force in the US 25 years ago. Bethan Hughes investigates the incentives and the remaining challenges for orphan drug development.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Rare incentives. Nat Rev Drug Discov 7, 190–191 (2008). https://doi.org/10.1038/nrd2546
Issue Date:
DOI: https://doi.org/10.1038/nrd2546
This article is cited by
-
Orphan products: an emerging trend in drug approvals
Nature Reviews Drug Discovery (2010)